Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.98-1.7%$6.08$3.21▼$8.40$1.75B0.624.11 million shs3.92 million shsPBYIPuma Biotechnology$7.26-2.6%$6.81$2.85▼$7.90$379.14M1.24266,455 shs352,272 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.69%+10.27%+17.31%-4.64%+88.65%PBYIPuma Biotechnology-2.55%-3.33%+4.16%+4.61%+142.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.98-1.7%$6.08$3.21▼$8.40$1.75B0.624.11 million shs3.92 million shsPBYIPuma Biotechnology$7.26-2.6%$6.81$2.85▼$7.90$379.14M1.24266,455 shs352,272 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.69%+10.27%+17.31%-4.64%+88.65%PBYIPuma Biotechnology-2.55%-3.33%+4.16%+4.61%+142.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$15.70124.93% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest PBYI and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/20/2026ARDXArdelyx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026ARDXArdelyx Williams TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.003/12/2026ARDXArdelyx Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform2/23/2026ARDXArdelyx WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$19.002/20/2026ARDXArdelyx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $18.002/20/2026ARDXArdelyx BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M4.23N/AN/A$0.60 per share11.63PBYIPuma Biotechnology$228.40M1.62$0.81 per share8.93$2.59 per share2.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A13.96N/A-13.58%-38.11%-11.85%N/APBYIPuma Biotechnology$31.11M$0.6111.9021.35N/A13.62%27.80%15.35%5/7/2026 (Estimated)Latest PBYI and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 million2/19/2026Q4 2025ARDXArdelyx$0.02-$0.01-$0.03-$0.01$118.04 million$125.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28PBYIPuma BiotechnologyN/A2.001.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million235.17 millionOptionablePBYIPuma Biotechnology20050.89 million39.03 millionOptionablePBYI and ARDX HeadlinesRecent News About These CompaniesPuma Biotech (PBYI) Reports Q1 Loss, Tops Revenue EstimatesMay 7 at 8:05 PM | zacks.comPuma Biotechnology Reports First Quarter 2026 Financial ResultsMay 7 at 4:05 PM | businesswire.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 159,200 Shares of Puma Biotechnology, Inc. $PBYIMay 7 at 8:33 AM | marketbeat.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving Average - Should You Sell?April 29, 2026 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsApril 23, 2026 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average - Should You Sell?April 21, 2026 | marketbeat.comPuma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth ManagementApril 12, 2026 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving Average - What's Next?April 8, 2026 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | businesswire.comPuma Biotechnology Stock Declines More Than 9% in a Month: Here's WhyMarch 18, 2026 | zacks.comIRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?March 12, 2026 | zacks.comPBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 ViewFebruary 27, 2026 | zacks.comPuma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...February 27, 2026 | finance.yahoo.comPuma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programsFebruary 26, 2026 | seekingalpha.comPuma Biotech (PBYI) Earnings Call TranscriptFebruary 26, 2026 | finance.yahoo.comPuma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comPuma Biotech (PBYI) Q4 Earnings and Revenues Beat EstimatesFebruary 26, 2026 | zacks.comPuma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | businesswire.comPuma Biotechnology to Present at TD Cowen’s 46th Annual Health Care ConferenceFebruary 23, 2026 | finance.yahoo.comPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial ResultsFebruary 12, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBYI and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$6.98 -0.12 (-1.69%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$6.99 +0.01 (+0.17%) As of 05/7/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.26 -0.19 (-2.55%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$7.35 +0.09 (+1.23%) As of 05/7/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
